Recovery from autoimmunity of MRL/lpr mice after infection with an interlukin-2/vaccinia recombinant...
Download
1 / 22

Objective - PowerPoint PPT Presentation


  • 112 Views
  • Uploaded on

Recovery from autoimmunity of MRL/lpr mice after infection with an interlukin-2/vaccinia recombinant virus Guitierrez J, Andreu J, Revilla Y, Vinuela E, Martinez C. Recovery from an autoimmunity of MRL/lpr mice after infection with an interlukin-2/vaccinia recombinant virus.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Objective' - sileas


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  • Recovery from autoimmunity of MRL/lpr mice after infection with an interlukin-2/vaccinia recombinant virus

  • Guitierrez J, Andreu J, Revilla Y, Vinuela E, Martinez C. Recovery from an autoimmunity of MRL/lpr mice after infection with an interlukin-2/vaccinia recombinant virus.

  • Presented by: Colleen Leonard


Objective
Objective with an interlukin-2/vaccinia recombinant virus

  • Examine the effects of IL-2 on the disease progression in MRL/lpr mice using live vaccinia recombinant viruses


  • MRL/lpr mice- with an interlukin-2/vaccinia recombinant virusstrain of systemic lupus erythematosus in mice that develops early in life.

  • SLE- autoimmune disease of humans usually involving anti-nuclear antibodies.

  • Autoimmunity- immune recognition and reaction against the individual’s own tissues.

  • IL-2- a molecule involved in signaling between cells of the immune system. Specifically a T-cell derived molecule implicated in the clonal expansion of antigen-activated T cells and in T-cell development.


  • Antigen- with an interlukin-2/vaccinia recombinant virus any molecule that can be specifically recognized by the adaptive elements of the immune system.

  • Antibody- molecule, produced by animals in response to antigen, that has a particular property of combining specifically with the antigen that induced it’s formation

  • T cells- lymphocytes that differentiate primarily in the thymus and are central to the control and development of immune responses.

  • CD4+T cells- helper cells which recognize an antigen in association with MHC Class II molecules.


  • CD8+T cells- with an interlukin-2/vaccinia recombinant virus cytotoxic cells that recognize antigens in association with MHC class I molecules.

  • MHC (major histocompatibility complex)- a set of genes found in all mammals whose products are primarily responsible for the rapid rejection of grafts between individuals, and function in signaling between lymphocytes and cells presenting antigen.

  • CD3-required for signal transduction following antigen recognition by the TCR heterodimer.


Rate of survival
Rate of survival with an interlukin-2/vaccinia recombinant virus

  • MRL/lpr mice infected with IL-2/vaccinia survived for more than a year compared with MRL/lpr mice treated with saline or infected with wild-type vaccinia.


Rate of survival1
Rate of Survival with an interlukin-2/vaccinia recombinant virus


Clinical symptoms
Clinical Symptoms with an interlukin-2/vaccinia recombinant virus

  • Survival was also accompanied by a lack of clinical symptoms such as arthritis, cutaneous ulcers and general deteritoration present in normal lpr mice was barely detectable after treatment.

  • The raised protein levels found in urine of non-infected MRL/lpr mice and MRL/lpr mice infected with wild type vaccinia virus, were significantly decreased in the recombinant-treated group.


Infiltration in kidney
Infiltration in kidney with an interlukin-2/vaccinia recombinant virus

  • Massive interstitial infiltration of the MRL/lpr kidney of the mouse infected with wild-type vaccinia.

  • Minimal mononuclear infiltration in kidney in the recombinant-treated mouse.


Glomerular size and cellularity
Glomerular size and cellularity with an interlukin-2/vaccinia recombinant virus

  • Increase in glomerular size and cellularity in the wild-type-infected mice.

  • The intraglomerular proliferation as well as glomerular enlargement were absent in kidneys from recombinant-infected mice.


Infiltration in synovial membrane
Infiltration in synovial membrane with an interlukin-2/vaccinia recombinant virus

  • Massive mononuclear infiltrate in wild-type-infected mice.

  • Absence of mononuclear infiltrate in recombinant infected mice.


Pre t stem cell development
Pre-T stem cell development with an interlukin-2/vaccinia recombinant virus

  • MRL/lpr disease is a result of a defect in pre-T stem-cell differentiation requiring thymus influence for the development of the full blown syndrome.

  • This syndrome is associated with the expansion of phenotypically immature double-negative cells as well as a marked decrease of immature ‘double positive’ thymocytes.


T cell development
T-cell development with an interlukin-2/vaccinia recombinant virus


Cytometric analysis of thymocytes
Cytometric analysis of thymocytes with an interlukin-2/vaccinia recombinant virus

  • Thymuses from recombinant-infected mice showed a significant reduction in double-negative cells accompanied by a three-fold increase in the immature double-positive CD4+CD8+ population.


Intrathymic differentiation maturation
Intrathymic differentiation-maturation with an interlukin-2/vaccinia recombinant virus

  • These data support the assertion that the IL-2/vaccinia recombinant treatment promotes the intrathymic differentiation-maturation of early T-cell precursors, resulting in a threefold expansion of CD4+ and CD8+ cells.


Accumulation of double negative cells
Accumulation of double-negative cells with an interlukin-2/vaccinia recombinant virus

  • Control mice showed hyperplasia of peripheral lymphoid organs produced by the accumulation of lymphocytes of phenotype CD3+CD4-CD8-.

  • Spleen, lymph node, and peritoneal cells were stained with anti-CD3, anti-CD4 and anti-CD8 monoclonal antibodies.


Cytometric analysis showing the reduction of cd3 cd4 cd8
Cytometric analysis showing the reduction of CD3+CD4-CD8- with an interlukin-2/vaccinia recombinant virus


Spleen
Spleen with an interlukin-2/vaccinia recombinant virus

  • Amount of CD3+ double-negative cells was reduced in the recombinant infected mice (from 20% to 3%).

  • Higher levels of mature cells (both CD4+CD8- and CD4-CD8+).


Lymph node
Lymph node with an interlukin-2/vaccinia recombinant virus

  • Amount of CD3+double negative cells was reduced in the recombinant infected mice (from 59% to 10%).

  • Higher levels of mature cells (both CD4+CD8- and CD4-CD8+).


Peritoneal cells
Peritoneal cells with an interlukin-2/vaccinia recombinant virus

  • Amount of CD3+double negative cells was reduced in the recombinant infected mice (from 17% to 4%).

  • Higher levels of mature cells (both CD4+CD8- and CD4-CD8+).


Conclusion
Conclusion with an interlukin-2/vaccinia recombinant virus

  • Vaccinated mice showed prolonged survival, marked attenuation of kidney interstitial infiltration and intraglomerular proliferation, as well as clearance of synovial mononuclear infiltrates.

  • Inoculation with the IL-2/vaccinia recombinant virus led, in addition, to drastic reduction of the double negative T-cell population, improved thymic differentiation and restoration of normal values of mature cells in peripheral lymphoid organs.


References
References with an interlukin-2/vaccinia recombinant virus

  • Boes M, Schmidt T, Linkemann K, Beaudette B, Rothstein A, and Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. PNAS. Vol 7:1184-1189. Feb. 2000.

  • Finck B. Linsley P, Wofsy D. Treatment of Murine Lupus with CTLA4Ig. Science Vol. 265 :1225-1227. August 1994.

  • Gutierrez J, Andreu J, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL/Ipr mice after infection with an interlukin-2/vaccinia recombinant virus. Nature Vol. 346:271-274. July 1990.

  • Roitt I, Brostoff J, and Male D. Immunology-Fifth Edition. 1998 Mosby International Ltd.


ad